WO2020122341A1 - Novel cinnamic acid derivative and antibacterial composition comprising same - Google Patents
Novel cinnamic acid derivative and antibacterial composition comprising same Download PDFInfo
- Publication number
- WO2020122341A1 WO2020122341A1 PCT/KR2019/008592 KR2019008592W WO2020122341A1 WO 2020122341 A1 WO2020122341 A1 WO 2020122341A1 KR 2019008592 W KR2019008592 W KR 2019008592W WO 2020122341 A1 WO2020122341 A1 WO 2020122341A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- cinnamic acid
- antibacterial
- acid derivative
- compound
- Prior art date
Links
- LNFHHSXNVWFJBW-BQYQJAHWSA-N CN(CC1)CCN1C(/C=C/c(cccc1)c1OC)=O Chemical compound CN(CC1)CCN1C(/C=C/c(cccc1)c1OC)=O LNFHHSXNVWFJBW-BQYQJAHWSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/76—1,3-Oxazoles; Hydrogenated 1,3-oxazoles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3544—Organic compounds containing hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- the present invention relates to a novel cinnamic acid derivative having excellent antibacterial effect. More particularly, the present invention relates to a novel cinnamic acid derivative having an antimicrobial effect and excellent water solubility and a composition comprising the same.
- cinnamic acid and cinnamon aldehydes which are natural products, are known to have antibacterial effects and are used in part, but first, they have low solubility (0.05% cinnamic acid and 0.2% 4-hydroxy cinnamic acid), and secondly, the applied pH changes from acidic to neutral. As it has a problem of losing activity, it has been difficult to apply for preservation in cosmetics and human products. It is also characteristic of preservatives in the general acid form. Ethyl ferulate among cinnamic acid derivatives is listed as a cosmetic raw material for antioxidant and preservative use, but it is hardly soluble in water and no examples have been used as product preservatives.
- the present inventors synthesized cinnamic acid amide derivatives of a novel structure as a result of research efforts to provide a compound derived from natural substances that can be prescribed for cosmetics and human products, and can replace preservatives, and these compounds have excellent antibacterial effects and excellent Since it has solubility, the present invention was completed by confirming that it is applicable to cosmetics and human products as a preservative.
- an object of the present invention is to provide a novel cinnamic acid derivative compound having both antibacterial activity and water solubility.
- Another object of the present invention is to provide a composition comprising the novel cinnamic acid derivative compound.
- Another object of the present invention is to provide products such as food, pharmaceuticals, quasi-drugs, household goods, and cosmetics containing the novel cinnamic acid derivative compounds.
- One aspect of the present invention is to provide a cinnamic acid derivative compound represented by Formula 1 below.
- R 1 is hydrogen, C 1 -C 2 alkyl, OH, OCH 3 , Cl or Br,
- R 2 is hydrogen, C 1 -C 2 alkyl, OH, OCH 3 , Cl or Br
- R 3 is hydrogen, C 1 -C 2 alkyl, OH, OCH 3 , Cl or Br; Or R 2 and R 3 are connected to each other to form a heterocycle containing an oxygen atom,
- A is NHR 21 , or ego,
- R 21 is (CH 2 ) m R 211 , m is an integer from 1 to 2, and R 211 is ego;
- R 22 is hydrogen, C 1 -C 2 alkyl, or Wherein R 221 is hydrogen, C 1 -C 2 alkyl, OH, OCH 3 , Cl or Br.
- the compound of the present invention Since the compound of the present invention has been little structurally studied, it was possible to significantly increase the solubility by introducing an alkylamide group or a cyclic amide group to cinnamic acid, and loses its activity when an acidic cinnamic acid compound is added to a neutral composition. Unlike it, it was confirmed that the compound of the present invention does not lose its activity even under a neutral pH condition and can be used by prescribing various pH conditions of cosmetics and human products.
- a preferred example of the cinnamic acid derivative of Formula 1 according to the present invention is a compound selected from Formulas 2 to 3 below.
- novel cinnamic acid derivative according to the present invention may be exemplified by the following compounds, but the following compounds are not intended to limit the present invention.
- the compound of Formula 1 may be synthesized through a coupling reaction between a cinnamic acid derivative and a primary or secondary amine derivative.
- the cinnamic acid derivative is used as a preservative, and can exhibit excellent antibacterial and antiseptic effects.
- the antimicrobial composition of the present invention may preferably have antibacterial activity against bacteria, fungi or yeast, more preferably Escherichia coli, Pseudomonas aeruginosa, Candida albicans, Black mold (Aspergillus niger) may have antibacterial activity at the same time, but is not limited thereto.
- antibacterial refers to the ability to resist bacteria, and means all mechanisms that are made to defend against the action of microorganisms such as bacteria, fungi, mold, yeast, and the like. It was confirmed that the composition containing the cinnamic acid derivative of the present invention has excellent antibacterial activity against microorganisms including bacteria, fungi and yeast.
- bacteria is a creature belonging to bacteria, the most mature species among living organisms, most of which are pathogenic bacteria and have the characteristics of prokaryotes, but do not have a nuclear membrane, mitochondrial, chloroplast-like structure. Sizes range from 0.5 ⁇ m to 0.5 mm.
- bacteria include, but are not limited to, Staphylococcus aureus ATCC 6538, Pseudomonas aeruginosa ATCC 15522, Escherichia coli ATCC10536, and the like. no.
- fungus collectively refers to a group of microorganisms composed of more than 72,000 species including fungi, yeast, mushrooms, belongs to eukaryotic organisms with a nuclear membrane, and cell organelles such as mitochondria, vesicles are developed, There are cell walls composed of chitin and glucan. Most of them are characterized by forming a mycelium that is cellular, renal, developing, and sexual and asexual reproduction. It forms a spore as a propagation body, but some fungi have unicellular proliferation. As a by-product, it is mainly involved in organic decomposition in nature, but some parasitic or symbiotic with plants and animals.
- the fungi include, but are not limited to, Aspergillus niger ATCC 9642 and Candida albicans ATCC 10231, for example.
- cinnamic acid derivative is used as a preservative, it can exhibit excellent antibacterial and antiseptic effect, and the content of the cinnamic acid derivative for this is 0.1 to 10% by weight (w/v) or 0.5 to 2% by weight of the total composition %(w/v). It has excellent antibacterial and preservation effect in the above content range. This is because if the content of the cinnamic acid derivative is less than 0.1% by weight, it does not greatly help the antibacterial and antiseptic effect, and when it exceeds 10% by weight, there is no increase in the apparent effect of increasing the content.
- the human body composition of the present invention may further include a chemical preservative in addition to the cinnamic acid derivative.
- the cinnamic acid derivative may be used together with a chemical preservative to produce a synergistic effect, thereby exhibiting more excellent antibacterial and antiseptic effects.
- the cinnamic acid derivative exhibits excellent antibacterial and antiseptic effects, and thus, even when a small amount of a chemical preservative is used, it can exhibit excellent antibacterial and antiseptic effects. Therefore, unlike the conventional cosmetic composition using an excessive amount of chemical preservatives causes skin side effects such as skin irritation and allergies, the human body composition of the present invention hardly causes skin side effects such as skin irritation and allergies.
- the chemical preservatives include, for example, 3-hexyloxy-1,2-propanediol, 1,2-hexanediol, polyols such as octanediol, parabens such as methylparaben, ethylparaben or propylparaben, And it may be used by mixing one, or two or more selected from the group consisting of phenoxyethanol and the like.
- the content of the chemical preservative may be 0.01 to 30% by weight, 0.1 to 10% by weight or 0.5 to 5% by weight based on the total weight of the total composition. In the above range, the synergistic effect with the cinnamic acid derivative is excellent, and if it exceeds 30% by weight, skin side effects such as skin irritation and allergy may occur.
- the cinnamic acid derivative compound of the present invention may have antibacterial activity and water solubility at the same time.
- the water solubility of the cinnamic acid derivative compound at room temperature (15 to 25°C) is 1 to 10%, preferably 1.5 to 5%, and 100 g of room temperature water contains 1 to 10 g of compounds, preferably 1.5 to 5 g. Can dissolve.
- Another aspect of the present invention is to provide a composition characterized in that it comprises the cinnamic acid derivative compound, or a salt, hydrate or solvate thereof.
- the salts include inorganic acids such as hydrochloride, hydrobromide or hydroiodide, acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, p-toluenesulfonate, bisulfate, sulfamate, sulfate, Naphthylate, butyrate, citrate, camphorate, camposulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, hep Formed with organic acids such as tanoate, hexanoate, 2-hydroxyethanesulfate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, tosylate
- Hydrate refers to a substance in which water is added to the compound or water enters as a constituent substance of the molecule
- a solvate refers to a higher-order compound formed between a molecule or ion of a solute and a molecule or ion of a solvent.
- the hydrate or solvate may be prepared using the above-described acids.
- the composition may be an antimicrobial composition, in which case it may be used with other ingredients, and may be appropriately formulated according to conventional methods. These other ingredients may be optionally selected and formulated according to the formulation or purpose of use of the antibacterial composition. For example, it may include a thickening agent, a stabilizer, a solubilizing agent, conventional adjuvants such as vitamins, pigments and fragrances, and a carrier.
- the antimicrobial composition of the present invention can be added to the cosmetic composition, antiseptic composition, pharmaceutical composition and quasi-drug composition for antibacterial.
- the antimicrobial composition containing the cinnamic acid derivative of the present invention as an active ingredient can be applied to any formulation, such as, for example, liquid, creamy, pasty, and solid phases, and its use can be applied to various fields.
- it can be applied to various cosmetic compositions such as human body-related cleaners such as whole body, skin, oral cavity, and hair.
- composition of the present invention is a cosmetic composition
- additional ingredients may be arbitrarily selected according to the formulation and purpose of use and appropriately formulated.
- additional ingredients may include conventional ingredients such as thickeners, surfactants, moisturizers, abrasives, sweeteners, pH adjusting agents, preservatives, binders, wetting agents, foaming agents, stabilizers, solubilizing agents, vitamins, pigments and flavoring agents.
- Another aspect of the present invention is to provide a product selected from the group consisting of food, pharmaceuticals, quasi-drugs, household products and cosmetics, as a product comprising the aforementioned composition.
- the food includes, but is not limited to, general food, health supplement food, health functional food, functional food, skin beauty food, animal food, and the like.
- the addition of the composition of the present invention to natural foods, processed foods, general food materials, etc. is also included in the scope of the foods of the present invention.
- the above medicine means a product used to treat diseases or relieve symptoms, including over-the-counter medicines, specialty medicines, oriental medicines, and animal medicines.
- Quasi-drugs include, but are not limited to, oral preparations, pesticides, pesticides, fungicides, disinfectants, anti-odor agents, soaking agents, contact lens care products, ointments, external disinfectants, vitamins and nutrient toners.
- Household goods include, but are not limited to, cleaning agents, laundry detergents, fabric softeners, dishwashing agents, fragrances, waxes, emulsifiers, lubricants, and the like.
- Cosmetics are products that are used in a similar way to clean and beautify the human body, add attractiveness, change the appearance brightly, or apply, rub, or spray on the human body to maintain or promote the health of the skin and hair. It refers to cosmetics for infants and toddlers, bath products, human body cleaning products, eye cosmetic products, fragrance products, hair dye products, color makeup products, hair products, nail products, shaving products, basic makeup products, And products for preventing body odor, but are not limited thereto.
- novel cinnamic acid derivative compound of the present invention has excellent water solubility with antibacterial activity, it has the advantage that it can be widely prescribed in various products, including water-based food, pharmaceuticals, quasi-drugs, household goods and cosmetics.
- novel cinnamic acid derivative according to the present invention has improved solubility, so it can be easily prescribed without the use of separate emulsifiers and solubilizers. It has stability under various pH conditions and excellent resistance to microorganisms. It can be used in various ways in the field of human products.
- CA-9 which is a representative example, was prepared as follows.
- 4-methoxy cinnaaldehyde (1) (5 g, 28 mmol, 1 eq) and thionyl chloride (3 mL, 42 mmol, 1.5 eq) were added to 30 mL of diclomethane and 50 The mixture was stirred for 4 hours. After completion of the reaction, the residual thionyl chloride and solvent were removed under reduced pressure to obtain 4-methoxy cinnamic acid chloride (2) in a liquid state with a dark yellow high viscosity.
- the 4-methoxy cinnamic acid salt (2) obtained in the above reaction was dissolved in 50 mL of dichloromethane, methyl piperazine (8.4 g, 84 mmol) was slowly dropped, and the mixture was stirred at room temperature for 12 hours. After completion of the reaction, the resulting amine salt solid was removed with a celite filter, and the organic layer was washed twice with purified water. The combined organic layers were dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to obtain CA-9 as a pale yellow solid (6.9 g, 94.7%).
- Cinnamic acid derivatives containing different substituents represented by [Chemical Formula 1] according to the present invention were prepared by the same reaction principle as the preparation example of CA-9, and compounds synthesized by nuclear magnetic resonance analysis were confirmed.
- the cinnamic acid derivatives of the present invention thus prepared and their NMR data are summarized in Table 1 below.
- the minimum inhibitory concentration (MIC) of cinnamic acid derivative was measured. Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa pre-cultured in liquid medium were cultured at 37° C. for 24 hours in 5 ml of brain heart infusion broth. , Candida albicans, Aspergillus niger were prepared by incubating potato dextrose broth in 5 ml at 30°C for 48 hours. A 2-fold dilution method was used to measure the MIC of the fermentation culture. Table 2 shows the results of the measurement of the minimum inhibitory concentration.
- the logP partition coefficient between octanol and water is a property commonly used in new drug development. The lower the value, the higher the polarity and the higher the water solubility.
- the logP values of various types of cinnamic acid derivative compounds were analyzed and the results are shown in Table 3 below.
- the logP value of compounds 11 to 14 (CA-2, CA-14, CA-9 and CA-17 compounds) is 1.4 or less. As a result, it was confirmed that it has properties that can be easily prescribed to cosmetics and household products containing water as a main component.
- Compound 5 was evaluated to have a logP value of 1.35, but the MIC was not able to be measured because of poor water solubility. The water solubility was 0.005%, and the water solubility was significantly lower than that of CA-9, which was 2%.
- CA-9 developed in the present invention has 2% water solubility at room temperature, and when heated to 40°C, it showed excellent results in that it dissolves well up to 5%.
- Emulsion-type shampoo was prepared by a conventional method using the composition components and contents shown in Table 5 below.
- the CA-9 and CA-12 compounds of the present invention were prepared using these two compounds because they were found to have high water solubility enough to produce an emulsion-type shampoo based on water.
- Example 1 Example 2
- Example 3 Example 4 CA-9 0.5 1.0 2.0 CA-12 2.0 Purified water To 100 To 100 To 100 To 100 Sodium laureth-2 sulfate 20 20 20 20
- Cocamidopropyl Betaine 20 20
- Polyquaternium-10 0.5 0.5 0.5 0.5 IDT 4
- bacteria that is, Staphylococcus aureus (Staphylococcus aureus ATCC 6538), Sedmonas aeruginosa (Pseudomonas aeruginosa ATCC 15522) and Escherichia coli (Escherichia coli ATCC10536)
- Staphylococcus aureus Staphylococcus aureus ATCC 6538
- Sedmonas aeruginosa Pseudomonas aeruginosa ATCC 15522
- Escherichia coli Escherichia coli ATCC10536
- test procedure using fungi is the same as the test procedure using bacteria, and Aspergillus niger ATCC 9642 and Candida albicans ATCC 10231 were used as fungi.
- Evaluation items The day the number of inoculum bacteria started to reach 20 CFU/g or less Example 1 Example 2 Example 3 Example 4 Germ 14 days 7 days 7 days 7 days Fungi 14 days 14 days 7 days 14 days 14 days
- Example 1 of the present invention was found to have excellent antibacterial and antiseptic effect by showing the number of fungi or bacteria below 20 CFU/g from the 14th day even though no chemical preservative was used.
- Example 3 containing more than 2% by weight of cinnamic acid derivatives, the number of fungi and bacteria rapidly decreased, indicating the number of fungi or bacteria of 20 CFU/g or less from the 7th day, and it was confirmed that the antibacterial and antiseptic effect was much better. Can be.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Dentistry (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The present invention relates to a novel cinnamic acid derivative having an excellent antibacterial effect and an antibacterial composition comprising same. Specifically, the present invention relates to an antibacterial composition comprising a cinnamic acid derivative having antibacterial activity against bacteria contaminating cosmetic products and, more specifically, to an antibacterial composition comprising a cinnamic acid derivative as an active ingredient against microorganisms contaminating cosmetic products and a cosmetic composition comprising same. The cinnamic acid derivative exhibits a broad spectrum of antibacterial activities against various bacteria and thus, the antibacterial composition comprising same can be advantageously used for sterile, antibacterial, and antiseptic purposes in various fields such as cosmetic products, medicines, daily supplies, agricultural chemicals, etc.
Description
본 출원은 2018년 12월 14일 출원된 대한민국출원 제10-2018-0162125호에 기초한 우선권을 주장하며, 해당 출원의 명세서 및 도면에 개시된 모든 내용은 본 출원에 원용된다.This application claims priority based on Republic of Korea Application No. 10-2018-0162125 filed on December 14, 2018, and all contents disclosed in the specification and drawings of the application are incorporated in this application.
본 발명은 우수한 항균 효과를 가지는 신규 계피산 유도체에 관한 것이다. 더 상세하게는 본 발명은 항균 효과 및 우수한 수용해성을 동시에 갖는 신규 계피산 유도체 및 이를 포함하는 조성물에 관한 것이다. The present invention relates to a novel cinnamic acid derivative having excellent antibacterial effect. More particularly, the present invention relates to a novel cinnamic acid derivative having an antimicrobial effect and excellent water solubility and a composition comprising the same.
우리 생활주변에서 널리 이용되는 식품, 의약품, 생활용품, 화장품 등의 많은 제품에는 보습제, 오일, 계면활성제, 무기분말, 유기 수용성 고분자, 향료 등의 다양한 재료들이 함유되어 있어 미생물이 성장하기에 적합한 상태이다. 따라서, 미생물에 의해 제품이 부패하는 것을 방지하고, 미생물을 경시적으로 사멸시켜 제품의 열화를 방지하기 위하여 화학적 방부제를 첨가하는 것이 일반적이다. 이러한 화학적 방부제로서 파라벤, 이미다졸리디닐 우레아, 페녹시 에탄올, 파라옥시안식향산 에스테르 또는 염화벤잘코늄 등이 일반적으로 사용되고 있다.Many products, such as foods, medicines, household goods, and cosmetics, which are widely used in our lives, contain various materials such as moisturizers, oils, surfactants, inorganic powders, organic water-soluble polymers, and fragrances, and are suitable for growing microorganisms. to be. Therefore, it is common to add a chemical preservative to prevent product decay by microorganisms and to kill microorganisms over time to prevent product degradation. As such a chemical preservative, paraben, imidazolidinyl urea, phenoxy ethanol, paraoxybenzoic acid ester or benzalkonium chloride is generally used.
그러나, 최근 단백질, 검, 비타민, 약용 식물 등 새로운 첨가물이 제품에 추가되면서, 미생물의 작용으로 인해 생기는 변화도 다양해지고 화학적 방부제에 의한 방부효과가 약해져, 화학적 방부제의 함량이 증가됨에 따라, 피부에 대한 자극, 알러지 증상 등이 유발되는 등 인체유해성의 문제점이 대두되고 있다.However, as new additives such as proteins, gums, vitamins, and medicinal plants have recently been added to the product, changes that occur due to the action of microorganisms are diversified and the preservative effect by chemical preservatives is weakened, and as the content of chemical preservatives increases, the skin Human irritation problems such as stimulation and allergic symptoms are being raised.
따라서, 화학적 방부제를 함유하지 않거나 적은 함량을 함유하여도 미생물에 의해 오염되지 않는 새로운 제품들이 요구되고 있다.Accordingly, there is a need for new products that do not contain chemical preservatives or contain small amounts, which are not contaminated by microorganisms.
한편, 천연물인 계피산 및 계피 알데히드는 항균효과가 있다고 알려져 부분적으로 사용되기도 하지만, 첫째로 용해도가 낮고(계피산 0.05%, 4-히드록시 계피산 0.2% 수준), 둘째로 적용 pH가 산성에서 중성으로 변화함에 따라 활성을 잃는 문제점이 있어 화장품 및 인체용품에서의 보존 용도로의 적용이 어려웠다. 이는 일반적인 산 형태의 보존제 특징이기도 하다. 계피산 유도체중 에틸 페룰레이트(Ethyl ferulate)가 산화방지제 및 방부제 용도로 화장품원료로 등재되어 있지만, 물에 거의 녹지 않으며, 제품 보존제로서 사용된 예는 알려진 바 없다.On the other hand, cinnamic acid and cinnamon aldehydes, which are natural products, are known to have antibacterial effects and are used in part, but first, they have low solubility (0.05% cinnamic acid and 0.2% 4-hydroxy cinnamic acid), and secondly, the applied pH changes from acidic to neutral. As it has a problem of losing activity, it has been difficult to apply for preservation in cosmetics and human products. It is also characteristic of preservatives in the general acid form. Ethyl ferulate among cinnamic acid derivatives is listed as a cosmetic raw material for antioxidant and preservative use, but it is hardly soluble in water and no examples have been used as product preservatives.
본 명세서 전체에 걸쳐 다수의 문헌이 참조되고 그 인용이 표시되어 있다. 인용된 문헌의 개시 내용은 그 전체로서 본 명세서에 참조로 삽입되어 본 발명이 속하는 기술 분야의 수준 및 본 발명의 내용이 보다 명확하게 설명된다. Numerous references are cited and cited throughout this specification. The disclosure content of the cited documents is incorporated by reference herein in its entirety and the level of the technical field to which the present invention pertains and the content of the present invention are more clearly described.
본 발명자들은 화장품 및 인체용품 등에 처방이 가능하며 방부제를 대체할 수 있는 천연물질 유래 화합물을 제공하기 위하여 연구 노력한 결과, 신규한 구조의 계피산 아마이드 유도체를 합성하고 이들 화합물이 우수한 항균 효과와 동시에 우수한 수용해성을 가지므로, 보존제로서 화장품 및 인체용품에 적용가능함을 확인해냄으로써, 본 발명을 완성하게 되었다. The present inventors synthesized cinnamic acid amide derivatives of a novel structure as a result of research efforts to provide a compound derived from natural substances that can be prescribed for cosmetics and human products, and can replace preservatives, and these compounds have excellent antibacterial effects and excellent Since it has solubility, the present invention was completed by confirming that it is applicable to cosmetics and human products as a preservative.
따라서 본 발명의 목적은 항균 활성 및 수용해성을 동시에 가지는 신규한 계피산 유도체 화합물을 제공하는 데 있다. Accordingly, an object of the present invention is to provide a novel cinnamic acid derivative compound having both antibacterial activity and water solubility.
본 발명의 다른 목적은 상기 신규한 계피산 유도체 화합물을 포함하는 조성물을 제공하는데 있다.Another object of the present invention is to provide a composition comprising the novel cinnamic acid derivative compound.
본 발명의 또 다른 목적은 상기 신규한 계피산 유도체 화합물을 포함하는 식품, 의약품, 의약외품, 생활용품 및 화장품 등의 제품을 제공하는데 있다.Another object of the present invention is to provide products such as food, pharmaceuticals, quasi-drugs, household goods, and cosmetics containing the novel cinnamic acid derivative compounds.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명, 청구범위 및 도면에 의해 보다 명확하게 된다. Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.
본 발명의 하나의 관점은 하기 화학식 1로 표시되는 계피산 유도체 화합물을 제공하는 것이다. One aspect of the present invention is to provide a cinnamic acid derivative compound represented by Formula 1 below.
<화학식 1><Formula 1>
상기 식에서,In the above formula,
R
1은 수소, C
1-C
2 알킬, OH, OCH
3, Cl 또는 Br이고,R 1 is hydrogen, C 1 -C 2 alkyl, OH, OCH 3 , Cl or Br,
R
2는 수소, C
1-C
2 알킬, OH, OCH
3, Cl 또는 Br이고, R
3는 수소, C
1-C
2 알킬, OH, OCH
3, Cl 또는 Br이거나; 또는 R
2 및 R
3은 서로 연결되어 산소원자를 포함하는 헤테로고리를 형성하고,R 2 is hydrogen, C 1 -C 2 alkyl, OH, OCH 3 , Cl or Br, R 3 is hydrogen, C 1 -C 2 alkyl, OH, OCH 3 , Cl or Br; Or R 2 and R 3 are connected to each other to form a heterocycle containing an oxygen atom,
여기서 R
21은 (CH
2)
mR
211이며, m은 1 내지 2의 정수이며, R
211은
이고;Where R 21 is (CH 2 ) m R 211 , m is an integer from 1 to 2, and R 211 is ego;
R
22는 수소, C
1-C
2 알킬, 또는
이며, 여기서 R
221은 수소, C
1-C
2 알킬, OH, OCH
3, Cl 또는 Br이다.R 22 is hydrogen, C 1 -C 2 alkyl, or Wherein R 221 is hydrogen, C 1 -C 2 alkyl, OH, OCH 3 , Cl or Br.
본 발명의 화합물은 구조적으로 연구가 거의 되어 있지 않은 바, 계피산에 알킬아미드기 혹은 사이클릭 아미드기를 도입함으로써 용해도를 크게 증가시킬 수 있었으며, 산성인 계피산 화합물이 중성 조성물에 첨가되었을 때 그 활성을 잃는 것과는 달리 본 발명의 화합물은 중성 pH 조건에서도 그 활성을 잃지 않아 화장품 및 인체용품의 다양한 pH조건에 처방하여 사용할 수 있음을 확인하였다.Since the compound of the present invention has been little structurally studied, it was possible to significantly increase the solubility by introducing an alkylamide group or a cyclic amide group to cinnamic acid, and loses its activity when an acidic cinnamic acid compound is added to a neutral composition. Unlike it, it was confirmed that the compound of the present invention does not lose its activity even under a neutral pH condition and can be used by prescribing various pH conditions of cosmetics and human products.
본 발명에 따른 상기 화학식 1의 계피산 유도체의 바람직한 예로는 하기 화학식 2 내지 화학식 3으로부터 선택되는 화합물이다.A preferred example of the cinnamic acid derivative of Formula 1 according to the present invention is a compound selected from Formulas 2 to 3 below.
<화학식 2><Formula 2>
<화학식 3><Formula 3>
또한, 본 발명에 따른 신규 계피산 유도체는 하기의 화합물로 예시될 수 있으나, 하기의 화합물들이 본 발명을 한정하는 것은 아니다.In addition, the novel cinnamic acid derivative according to the present invention may be exemplified by the following compounds, but the following compounds are not intended to limit the present invention.
본 발명에 따른 상기 화학식 1의 계피산 유도체 화합물들의 합성 반응의 예시를 아래 반응식 1에 나타내었다.An example of the synthetic reaction of the cinnamic acid derivative compounds of Formula 1 according to the present invention is shown in Scheme 1 below.
<반응식 1><Scheme 1>
상기 반응식 1에 나타낸 바와 같이 화학식 1의 화합물은 계피산 유도체와 1차 또는 2차 아민 유도체의 커플링 반응을 통해 합성될 수 있다.As shown in Reaction Scheme 1, the compound of Formula 1 may be synthesized through a coupling reaction between a cinnamic acid derivative and a primary or secondary amine derivative.
본 발명에서 계피산 유도체는 보존제로서 사용되어, 우수한 항균 및 방부 효과를 발휘할 수 있다. 구체적으로, 본 발명의 항균용 조성물은 바람직하게는 세균, 진균 또는 효모에 대해 항균 활성을 가질 수 있으며, 더욱 바람직하게는 대장균 (Escherichia coli), 녹농균 (Pseudomonas aeruginosa), 칸디다균 (Candida albicans), 흑곰팡이(Aspergillus niger)에 동시에 항균 활성을 가질 수 있으나, 이에 제한되지 않는다.In the present invention, the cinnamic acid derivative is used as a preservative, and can exhibit excellent antibacterial and antiseptic effects. Specifically, the antimicrobial composition of the present invention may preferably have antibacterial activity against bacteria, fungi or yeast, more preferably Escherichia coli, Pseudomonas aeruginosa, Candida albicans, Black mold (Aspergillus niger) may have antibacterial activity at the same time, but is not limited thereto.
본 발명에서 용어, "항균"은 균에 저항하는 능력을 의미하며, 세균이나 진균, 곰팡이, 효모 등과 같은 미생물의 작용으로부터 방어하기 위해 이루어지는 모든 기작을 의미한다. 본 발명의 계피산 유도체를 포함하는 조성물은 세균, 진균 및 효모를 포함하는 미생물에 대한 항균 활성이 뛰어난 것을 확인하였다.In the present invention, the term "antibacterial" refers to the ability to resist bacteria, and means all mechanisms that are made to defend against the action of microorganisms such as bacteria, fungi, mold, yeast, and the like. It was confirmed that the composition containing the cinnamic acid derivative of the present invention has excellent antibacterial activity against microorganisms including bacteria, fungi and yeast.
본 발명에서 용어, "세균"은 박테리아에 속하는 생물로서, 생명체들 중에 가장 많이 번성한 종으로 대부분 병원성 균이며 원핵생물의 특징을 그대로 가지고 있으나, 핵막이나 미토콘드리아, 엽록체와 같은 구조는 가지고 있지 않다. 크기는 0.5 μm 부터 0.5 mm까지 다양하다. 상기 세균으로는 예를 들어, 스타필로코커스 아우레우스 (Staphylococcus aureus ATCC 6538), 세도모나스 애루지노사 (Pseudomonas aeruginosa ATCC 15522) 및 에스케리치아 콜라이 (Escherichia coli ATCC10536) 등을 포함하나 이에 제한되는 것은 아니다.In the present invention, the term "bacteria" is a creature belonging to bacteria, the most prosperous species among living organisms, most of which are pathogenic bacteria and have the characteristics of prokaryotes, but do not have a nuclear membrane, mitochondrial, chloroplast-like structure. Sizes range from 0.5 μm to 0.5 mm. Such bacteria include, but are not limited to, Staphylococcus aureus ATCC 6538, Pseudomonas aeruginosa ATCC 15522, Escherichia coli ATCC10536, and the like. no.
본 발명에서 용어, "진균"은 곰팡이, 효모, 버섯을 포함한 72,000종 이상의 균종으로 구성되는 미생물군을 총칭 하며, 핵막이 있는 진핵생물에 속하고, 미토콘드리아, 소포체 등의 세포 소기관이 발달해 있으며, 키틴, 글루칸 등으로 구성된 세포벽이 있다. 대부분은 세포성인 균사를 형성하여 신장, 발육하고 유성생식 및 무성생식을 하는 것이 특징이다. 번식체로 포자를 형성하지만 일부 균종은 단세포성 증식을 한다. 주로 부생균으로서 자연계의 유기분해에 관여하지만, 일부는 동식물에 기생 또는 공생한다. 상기 진균에는 예를 들어, 아스퍼질러스 나이거 (Aspergillus niger ATCC 9642) 및 칸디다 알비칸스 (Candida albicans ATCC 10231) 등이 포함되나 이에 제한되는 것은 아니다.In the present invention, the term, "fungus" collectively refers to a group of microorganisms composed of more than 72,000 species including fungi, yeast, mushrooms, belongs to eukaryotic organisms with a nuclear membrane, and cell organelles such as mitochondria, vesicles are developed, There are cell walls composed of chitin and glucan. Most of them are characterized by forming a mycelium that is cellular, renal, developing, and sexual and asexual reproduction. It forms a spore as a propagation body, but some fungi have unicellular proliferation. As a by-product, it is mainly involved in organic decomposition in nature, but some parasitic or symbiotic with plants and animals. The fungi include, but are not limited to, Aspergillus niger ATCC 9642 and Candida albicans ATCC 10231, for example.
본 발명에서 계피산 유도체는 보존제로서 사용되어, 우수한 항균 및 방부 효과를 발휘할 수 있으며, 이를 위한 상기 계피산 유도체의 함량은 전체 조성물 총 중량에 대하여 0.1 내지 10 중량%(w/v) 또는 0.5 내지 2 중량%(w/v)로 포함될 수 있다. 상기 함량 범위에서 항균 및 보존 효과가 우수하다. 상기 계피산 유도체의 함량이 0.1 중량% 미만이면 항균 및 방부 효과에 크게 도움이 되지 않으며, 10 중량%를 초과하면 함유량 증가에 따른 뚜렷한 효과의 증가가 나타나지 않기 때문이다.In the present invention, cinnamic acid derivative is used as a preservative, it can exhibit excellent antibacterial and antiseptic effect, and the content of the cinnamic acid derivative for this is 0.1 to 10% by weight (w/v) or 0.5 to 2% by weight of the total composition %(w/v). It has excellent antibacterial and preservation effect in the above content range. This is because if the content of the cinnamic acid derivative is less than 0.1% by weight, it does not greatly help the antibacterial and antiseptic effect, and when it exceeds 10% by weight, there is no increase in the apparent effect of increasing the content.
또한, 본 발명의 인체용품 조성물은 계피산 유도체 외에 화학적 방부제를 추가로 포함할 수 있다. 이 경우, 계피산 유도체는 화학적 방부제와 함께 사용되어, 시너지 효과가 발생하여 더욱 뛰어난 항균 및 방부 효과를 발휘할 수 있다. 구체적으로, 상기 계피산 유도체는 우수한 항균 및 방부 효과를 발휘하므로, 미량의 화학적 방부제를 사용하여도 뛰어난 항균 및 방부 효과를 발휘할 수 있다. 따라서, 과량의 화학적 방부제를 사용하는 종래의 화장료 조성물이 피부 자극 및 알러지 등의 피부 부작용을 일으키는 것과 달리, 본 발명의 인체용품 조성물은 피부 자극 및 알러지 등의 피부 부작용을 거의 일으키지 않는다.In addition, the human body composition of the present invention may further include a chemical preservative in addition to the cinnamic acid derivative. In this case, the cinnamic acid derivative may be used together with a chemical preservative to produce a synergistic effect, thereby exhibiting more excellent antibacterial and antiseptic effects. Specifically, the cinnamic acid derivative exhibits excellent antibacterial and antiseptic effects, and thus, even when a small amount of a chemical preservative is used, it can exhibit excellent antibacterial and antiseptic effects. Therefore, unlike the conventional cosmetic composition using an excessive amount of chemical preservatives causes skin side effects such as skin irritation and allergies, the human body composition of the present invention hardly causes skin side effects such as skin irritation and allergies.
상기 화학적 방부제로는 예를 들어, 3-헥실옥시-1,2-프로판다이올, 1,2-헥산다이올, 옥탄다이올과 같은 폴리올, 메틸파라벤, 에틸파라벤 또는 프로필파라벤 등의 파라벤, 및 페녹시에탄올 등으로 이루어진 그룹으로부터 선택된 하나, 또는 둘 이상 혼합하여 사용할 수 있다.The chemical preservatives include, for example, 3-hexyloxy-1,2-propanediol, 1,2-hexanediol, polyols such as octanediol, parabens such as methylparaben, ethylparaben or propylparaben, And it may be used by mixing one, or two or more selected from the group consisting of phenoxyethanol and the like.
상기 화학적 방부제의 함량은 전체 조성물 총 중량에 대하여 0.01 내지 30 중량%, 0.1 내지 10 중량% 또는 0.5 내지 5 중량%일 수 있다. 상기 범위에서 계피산 유도체와 시너지 효과가 우수하며, 30 중량%를 초과하면 피부 자극 및 알러지 등의 피부 부작용이 발생할 우려가 있다.The content of the chemical preservative may be 0.01 to 30% by weight, 0.1 to 10% by weight or 0.5 to 5% by weight based on the total weight of the total composition. In the above range, the synergistic effect with the cinnamic acid derivative is excellent, and if it exceeds 30% by weight, skin side effects such as skin irritation and allergy may occur.
또한, 본 발명의 계피산 유도체 화합물은 항균 활성 및 수용해성을 동시에 가질 수 있다. 이 경우 상기 계피산 유도체 화합물의 상온(15~25℃)에서의 수용해도는 1 내지 10%, 바람직하게는 1.5 내지 5%로서, 상온의 물 100g에 화합물 1 내지 10g, 바람직하게는 1.5 내지 5g이 용해될 수 있다. In addition, the cinnamic acid derivative compound of the present invention may have antibacterial activity and water solubility at the same time. In this case, the water solubility of the cinnamic acid derivative compound at room temperature (15 to 25°C) is 1 to 10%, preferably 1.5 to 5%, and 100 g of room temperature water contains 1 to 10 g of compounds, preferably 1.5 to 5 g. Can dissolve.
본 발명의 다른 관점은 상기 계피산 유도체 화합물, 또는 그의 염, 수화물 또는 용매화물을 포함하는 것을 특징으로 하는 조성물을 제공하는 것이다. Another aspect of the present invention is to provide a composition characterized in that it comprises the cinnamic acid derivative compound, or a salt, hydrate or solvate thereof.
상기 염은 하이드로클로라이드, 하이드로브로마이드 또는 하이드로요오다이드와 같은 무기산, 아세테이트, 아디페이트, 알기네이트, 아스파르테이트, 벤조에이트, 벤젠술포네이트, p-톨루엔설포네이트, 비설페이트, 설파메이트, 설페이트, 나프틸레이트, 부티레이트, 시트레이트, 캄포레이트, 캄포설포네이트, 시클로펜탄프로피오네이트, 디글루코네이트, 도데실설페이트, 에탄설포네이트, 푸마레이트, 글루코헵타노에이트, 글리세로포스페이트, 헤미설페이트, 헵타노에이트, 헥사노에이트, 2-히드록시에탄설페이트, 락테이트, 말리에이트, 메탄설포네이트, 2-나프탈렌설포네이트, 니코티네이트, 옥살레이트, 토실레이트 또는 운데카노에이트와 같은 유기산을 이용하여 형성될 수 있다. The salts include inorganic acids such as hydrochloride, hydrobromide or hydroiodide, acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, p-toluenesulfonate, bisulfate, sulfamate, sulfate, Naphthylate, butyrate, citrate, camphorate, camposulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, hep Formed with organic acids such as tanoate, hexanoate, 2-hydroxyethanesulfate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, tosylate or undecanoate Can be.
수화물은 상기 화합물에 물이 더해지거나 분자의 구성 물질로 물이 들어간 물질을 말하며, 용매화물은 용질의 분자나 이온과 용매의 분자나 이온 사이에 생긴 고차의 화합물을 의미한다. 상기 수화물 또는 용매화물은 전술한 산을 이용하여 제조될 수도 있다.Hydrate refers to a substance in which water is added to the compound or water enters as a constituent substance of the molecule, and a solvate refers to a higher-order compound formed between a molecule or ion of a solute and a molecule or ion of a solvent. The hydrate or solvate may be prepared using the above-described acids.
상기 조성물은 항균 조성물일 수 있는데, 이 경우 다른 성분들과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 제형화 될 수 있다. 이러한 다른 성분들은 항균 조성물의 제형 또는 사용목적 등에 따라 임의로 선정하여 배합할 수 있다. 예를 들어, 점증제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 및 담체 등을 포함할 수 있다. The composition may be an antimicrobial composition, in which case it may be used with other ingredients, and may be appropriately formulated according to conventional methods. These other ingredients may be optionally selected and formulated according to the formulation or purpose of use of the antibacterial composition. For example, it may include a thickening agent, a stabilizer, a solubilizing agent, conventional adjuvants such as vitamins, pigments and fragrances, and a carrier.
본 발명의 항균용 조성물은 화장료 조성물, 방부제 조성물, 약학적 조성물 및 의약외품 조성물에 항균을 위하여 첨가할 수 있다. 본 발명의 계피산 유도체를 유효성분으로 함유하는 항균용 조성물은 예를 들면, 액상, 크림상, 페이스트상, 고체상 등 어떠한 제형으로도 응용될 수 있으며, 그 용도는 다양한 분야에 적용될 수 있다. 예를 들면, 전신, 피부, 구강, 모발 등 인체관련 세정제 등 각종 화장료 조성물 등에 적용될 수 있다.The antimicrobial composition of the present invention can be added to the cosmetic composition, antiseptic composition, pharmaceutical composition and quasi-drug composition for antibacterial. The antimicrobial composition containing the cinnamic acid derivative of the present invention as an active ingredient can be applied to any formulation, such as, for example, liquid, creamy, pasty, and solid phases, and its use can be applied to various fields. For example, it can be applied to various cosmetic compositions such as human body-related cleaners such as whole body, skin, oral cavity, and hair.
본 발명의 조성물이 화장료 조성물인 경우 당업계에 공지된 화장품의 형태로 다양하게 제형화될 수 있으며, 그 제형 및 사용목적에 따라 추가의 성분을 임의로 선정하여 적절히 배합할 수 있다. 예를 들어, 점증제, 계면활성제, 보습제, 연마제, 감미제, pH조정제, 방부제, 결합제, 습윤제, 기포제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 성분을 포함할 수 있다.When the composition of the present invention is a cosmetic composition, it may be variously formulated in the form of cosmetics known in the art, and additional ingredients may be arbitrarily selected according to the formulation and purpose of use and appropriately formulated. For example, it may include conventional ingredients such as thickeners, surfactants, moisturizers, abrasives, sweeteners, pH adjusting agents, preservatives, binders, wetting agents, foaming agents, stabilizers, solubilizing agents, vitamins, pigments and flavoring agents.
본 발명의 또 다른 관점은 전술한 조성물을 포함하는 제품으로서, 식품, 의약품, 의약외품, 생활용품 및 화장품으로 이루어진 군으로부터 선택되는 제품을 제공하는 것이다.Another aspect of the present invention is to provide a product selected from the group consisting of food, pharmaceuticals, quasi-drugs, household products and cosmetics, as a product comprising the aforementioned composition.
상기 식품은 일반 식품, 건강보조식품, 건강기능식품, 기능성 식품, 피부미용 식품, 동물 식품 등을 포함하며 이에 제한되는 것은 아니다. 천연식품, 가공식품, 일반적인 식자재 등에 본 발명의 조성물을 첨가한 것도 본 발명의 식품의 범위에 포함된다. The food includes, but is not limited to, general food, health supplement food, health functional food, functional food, skin beauty food, animal food, and the like. The addition of the composition of the present invention to natural foods, processed foods, general food materials, etc. is also included in the scope of the foods of the present invention.
상기 의약품은 일반의약품, 전문의약품, 한의약품 및 동물의약품을 포함하여 질병을 치료하거나 증상을 완화하는 데 쓰이는 제품을 의미한다.The above medicine means a product used to treat diseases or relieve symptoms, including over-the-counter medicines, specialty medicines, oriental medicines, and animal medicines.
의약외품은 구강제제, 살충제, 살서제, 살균제, 소독제제, 액취방지제, 짓무름용제, 콘택트렌즈관리용품, 연고제, 외용 소독제, 비타민 및 자양강장제 등의 내복용 제제 등을 포함하며 이에 제한되는 것은 아니다.Quasi-drugs include, but are not limited to, oral preparations, pesticides, pesticides, fungicides, disinfectants, anti-odor agents, soaking agents, contact lens care products, ointments, external disinfectants, vitamins and nutrient toners.
생활용품은 청소용 제제, 세탁용 세제, 섬유유연제, 주방세제, 방향제, 왁스, 유화제, 윤활제 등을 포함하며 이에 제한되는 것은 아니다.Household goods include, but are not limited to, cleaning agents, laundry detergents, fabric softeners, dishwashing agents, fragrances, waxes, emulsifiers, lubricants, and the like.
화장품은 인체를 청결·미화하여 매력을 더하고 용모를 밝게 변화시키거나 피부·모발의 건강을 유지 또는 증진하기 위하여 인체에 바르고 문지르거나 뿌리는 등 이와 유사한 방법으로 사용되는 물품으로서 인체에 대한 작용이 경미한 것을 말하며, 영유아용 화장품, 목욕용 제품, 인체 세정용 제품류, 눈 화장용 제품, 방향용 제품, 두발 염색용 제품, 색조 화장 제품, 두발용 제품, 손발톱용 제품, 면도용 제품, 기초화장용 제품, 체취 방지용 제품 등을 포함하며 이에 제한되는 것은 아니다.Cosmetics are products that are used in a similar way to clean and beautify the human body, add attractiveness, change the appearance brightly, or apply, rub, or spray on the human body to maintain or promote the health of the skin and hair. It refers to cosmetics for infants and toddlers, bath products, human body cleaning products, eye cosmetic products, fragrance products, hair dye products, color makeup products, hair products, nail products, shaving products, basic makeup products, And products for preventing body odor, but are not limited thereto.
본 발명의 신규한 계피산 유도체 화합물은 항균력과 함께 우수한 수용해성을 갖기 때문에 물을 기본으로 하는 식품, 의약품, 의약외품, 생활용품 및 화장품을 포함하여 다양한 제품에 널리 처방이 가능하다는 장점이 있다.Since the novel cinnamic acid derivative compound of the present invention has excellent water solubility with antibacterial activity, it has the advantage that it can be widely prescribed in various products, including water-based food, pharmaceuticals, quasi-drugs, household goods and cosmetics.
본 발명에 따른 신규 계피산 유도체는 용해도가 향상되어 별도의 유화제 및 가용화제를 사용하지 않아도 쉽게 처방이 가능하며, 다양한 pH조건에서의 안정성과 미생물에 대한 우수한 저항성을 가져 화학적 방부제를 사용하지 않은 화장품 및 인체용품 분야 등에서 다양하게 활용이 가능하다.The novel cinnamic acid derivative according to the present invention has improved solubility, so it can be easily prescribed without the use of separate emulsifiers and solubilizers. It has stability under various pH conditions and excellent resistance to microorganisms. It can be used in various ways in the field of human products.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명 하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 있어서 자명할 것이다. Hereinafter, the present invention will be described in more detail through examples. These examples are only for explaining the present invention in more detail, it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.
실시예Example
1. 계피산 유도체의 합성1. Synthesis of cinnamonic acid derivatives
본 발명에 따른 [화학식 1]로 표시되는 계피산 유도체 중에서 대표적인 예인 CA-9를 하기와 같이 제조하였다.Among the cinnamic acid derivatives represented by [Chemical Formula 1] according to the present invention, CA-9, which is a representative example, was prepared as follows.
구체적으로 하기 <반응식 2>에 따라서 4-메톡시 시남알데히드(1)(5g, 28 mmol, 1당량)과 염화티오닐 (3 mL, 42 mmol, 1.5 당량)을 디클로메탄 30 mL에 넣고 50도에서 4시간 동안 교반하였다. 반응 종료 후, 감압하여 잔류 염화티오닐과 용제를 제거하여 4-메톡시 시나믹산염화물(2)를 짙은 노란색의 점도 높은 액체상태로 얻었다. 상기 반응에서 수득한 4-메톡시 시나믹산염화물(2)을 디클로로메탄 50 mL에 녹이고, 메틸 피페라진(8.4 g, 84 mmol)을 천천히 떨어뜨리고, 상온에서 12시간 교반한다. 반응종료 후, 생성된 아민염 고체를 셀라이트 필터로 제거한 뒤, 유기층을 정제수로 2번 씻어내었다. 유기층을 모아서 무수황산마그네슘으로 건조하고, 감압하여 용제를 제거하여 옅은 노란색 고체인 CA-9을 얻었다(6.9g, 94.7%). 1H NMR (400 MHz, CDCl3-d3) δ 2.3 (s, 3H), 2.42-2.44 (m, 4H), 3.68-3.71 (m, 4H), 3.78 (s, 3H), 6.73 (d, J = 15.2, 1H), 6.85 (d, J=8.4, 2H) 7.43 (d, J=8.4, 2H), 7.61 (d, J=15.2, 1H).Specifically, according to <Scheme 2>, 4-methoxy cinnaaldehyde (1) (5 g, 28 mmol, 1 eq) and thionyl chloride (3 mL, 42 mmol, 1.5 eq) were added to 30 mL of diclomethane and 50 The mixture was stirred for 4 hours. After completion of the reaction, the residual thionyl chloride and solvent were removed under reduced pressure to obtain 4-methoxy cinnamic acid chloride (2) in a liquid state with a dark yellow high viscosity. The 4-methoxy cinnamic acid salt (2) obtained in the above reaction was dissolved in 50 mL of dichloromethane, methyl piperazine (8.4 g, 84 mmol) was slowly dropped, and the mixture was stirred at room temperature for 12 hours. After completion of the reaction, the resulting amine salt solid was removed with a celite filter, and the organic layer was washed twice with purified water. The combined organic layers were dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to obtain CA-9 as a pale yellow solid (6.9 g, 94.7%). 1H NMR (400 MHz, CDCl3-d3) δ 2.3 (s, 3H), 2.42-2.44 (m, 4H), 3.68-3.71 (m, 4H), 3.78 (s, 3H), 6.73 (d, J = 15.2 , 1H), 6.85 (d, J=8.4, 2H) 7.43 (d, J=8.4, 2H), 7.61 (d, J=15.2, 1H).
<반응식 2><Reaction Scheme 2>
CA-9의 제조예와 동일한 반응 원리에 의하여 본 발명에 따른 [화학식 1]로 표시되는 상이한 치환기를 포함하는 계피산 유도체들을 제조하고 핵자기공명분석법에 의하여 합성된 화합물들을 확인하였다. 이와 같이 제조한 본원발명의 계피산 유도체들 및 이들의 NMR 데이터를 하기 표 1에 정리하였다.Cinnamic acid derivatives containing different substituents represented by [Chemical Formula 1] according to the present invention were prepared by the same reaction principle as the preparation example of CA-9, and compounds synthesized by nuclear magnetic resonance analysis were confirmed. The cinnamic acid derivatives of the present invention thus prepared and their NMR data are summarized in Table 1 below.
2. 미생물 최소 억제 농도(2. Minimum microbial inhibitory concentration (
MICMIC
) 평가) evaluation
계피산 유도체의 최소저해농도(Minimum Inhibition Concentration: MIC)를 측정하였다. 액상배지에 전 배양한 스타필로코커스 아우레우스 (Staphylococcus aureus), 에스케리치아 콜라이(Escherichia coli), 세도모나스 애루지노사(Pseudomonas aeruginosa)는 뇌 심장 인퓨전 브로스 5 ml에 37℃, 24시간 배양하고, Candida albicans, Aspergillus niger는 감자 덱스트로스 브로스 5 ml에 30℃, 48시간 배양하여 준비하였다. 발효배양물의 MIC를 측정하기 위해서 2배 희석법을 사용하였다. 최소저해농도를 측정한 결과를 하기 표 2에 나타내었다.The minimum inhibitory concentration (MIC) of cinnamic acid derivative was measured. Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa pre-cultured in liquid medium were cultured at 37° C. for 24 hours in 5 ml of brain heart infusion broth. , Candida albicans, Aspergillus niger were prepared by incubating potato dextrose broth in 5 ml at 30°C for 48 hours. A 2-fold dilution method was used to measure the MIC of the fermentation culture. Table 2 shows the results of the measurement of the minimum inhibitory concentration.
SampleSample | 세균 (ppm)Bacteria (ppm) | 진균 (ppm)Fungi (ppm) | |||
S. aureusS. aureus | E. coliE. coli | P. aeruginosaP. aeruginosa | C. albicansC. albicans | A. nigerA. niger | |
CA-9CA-9 | 313313 | 313313 | 625625 | 313313 | 313313 |
CA-12CA-12 | 12501250 | 625625 | 625625 | 313313 | 313313 |
CA-13CA-13 | 12501250 | >2500>2500 | 12501250 | 313313 | 313313 |
CA-16CA-16 | 625625 | 625625 | 625625 | 313-313- | 313313 |
CA-17CA-17 | 625625 | 625625 | 625625 | 313313 | 313313 |
실험결과 본 발명의 계피산 유도체 화합물들은 우수한 항균 효과를 갖는 것으로 확인되었다.As a result of the experiment, it was confirmed that the cinnamic acid derivative compounds of the present invention have excellent antibacterial effects.
3. 수용해도 테스트3. Water solubility test
(1) logP값 분석(1) logP value analysis
logP (옥탄올과 물 사이의 분배계수) 값은 신약개발에서 많이 사용되는 물성으로서 값이 낮을수록 극성이 높으며 수용해성이 높다고 통용되는 물성이다. 여러 종류의 계피산 유도체 화합물들에 대하여 logP값 분석하고 그 결과를 하기 표 3에 나타내었다.The logP (partition coefficient between octanol and water) is a property commonly used in new drug development. The lower the value, the higher the polarity and the higher the water solubility. The logP values of various types of cinnamic acid derivative compounds were analyzed and the results are shown in Table 3 below.
상기 화합물들에 대하여 수용해성과 관련이 큰 물성이 logP 값에 대하여 평가해본 결과, 11~14번 화합물(CA-2, CA-14, CA-9 및 CA-17 화합물)은 logP값이 1.4 이하로서 물을 주성분으로 포함되는 화장품 및 생활용품에 용이하게 처방할 수 있는 특성을 갖는 것으로 확인되었다. 5번 화합물은 logP값이 1.35로 평가되었지만 실제로 수용해성이 좋지 않아서 MIC 측정 불가했으며, 수용해도는 0.005%로서, 수용해도가 2%인 CA-9에 비해서 수용해성이 현저히 낮은 것으로 확인되었다. As a result of evaluating the logP value for physical properties having a high water solubility with respect to the above compounds, the logP value of compounds 11 to 14 (CA-2, CA-14, CA-9 and CA-17 compounds) is 1.4 or less. As a result, it was confirmed that it has properties that can be easily prescribed to cosmetics and household products containing water as a main component. Compound 5 was evaluated to have a logP value of 1.35, but the MIC was not able to be measured because of poor water solubility. The water solubility was 0.005%, and the water solubility was significantly lower than that of CA-9, which was 2%.
(2) 수용해도 측정(2) Water solubility measurement
계피산 및 계피산 유도체의 수용해도를 측정하여 하기 표 4에 비교하였다. 본 발명에서 개발한 CA-9 은 상온에서 2% 수용해를 가지며, 40도로 가온시에는 5%까지 용해가 잘 되는 우수한 결과를 보였다. The water solubility of cinnamic acid and cinnamic acid derivatives was measured and compared to Table 4 below. CA-9 developed in the present invention has 2% water solubility at room temperature, and when heated to 40°C, it showed excellent results in that it dissolves well up to 5%.
계피산Cinnamon | 계피산 메틸 에스테르Cinnamic acid methyl ester | 계피산 알데하이드Cinnamic acid aldehyde | CA-9CA-9 | |
수용해도 (%)Water solubility (%) | 0.050.05 | InsolublsInsolubls | Slightly solubleSlightly soluble | 22 |
4. 계피산 유도체를 포함하는 샴푸제조 및 항균효과 확인4. Preparation of shampoo containing cinnamonic acid derivatives and confirmation of antibacterial effect
하기 표 5에 나타낸 조성 성분과 함량을 사용하여 통상적인 방법으로 에멀전 타입의 샴푸를 제조하였다. 본 발명의 CA-9 및 CA-12 화합물은 물을 주성분으로 하는 에멀전 타입의 샴푸를 제조할 수 있을 정도로 수용해도가 높은 것으로 확인되었기에 이 두 화합물을 사용하여 제조하였다.Emulsion-type shampoo was prepared by a conventional method using the composition components and contents shown in Table 5 below. The CA-9 and CA-12 compounds of the present invention were prepared using these two compounds because they were found to have high water solubility enough to produce an emulsion-type shampoo based on water.
원료성분명Ingredient name | 실시예 1Example 1 | 실시예 2Example 2 | 실시예 3Example 3 | 실시예 4Example 4 |
CA-9CA-9 | 0.50.5 | 1.01.0 | 2.02.0 | |
CA-12CA-12 | 2.02.0 | |||
정제수Purified water | To 100To 100 | To 100To 100 | To 100To 100 | To 100To 100 |
소듐라우레스-2설페이트Sodium laureth-2 sulfate | 2020 | 2020 | 2020 | 2020 |
코카미도프로필베타인Cocamidopropyl Betaine | 2020 | 2020 | 2020 | 2020 |
폴리쿼터늄-10Polyquaternium-10 | 0.50.5 | 0.50.5 | 0.50.5 | 0.50.5 |
이디티에이4나트륨IDT 4 Sodium | 0.050.05 | 0.050.05 | 0.050.05 | 0.050.05 |
구연산Citric acid | 0.040.04 | 0.40.4 | 0.040.04 | 0.040.04 |
상기 제조한 실시예 1 내지 4의 조성물의 항균 및 방부 효과를 실험하기 위하여 세균 또는 진균을 시료에 첨가하고 접종균 수의 변화를 체크하였으며, 진균 또는 세균의 수가 20 CFU/g 이하가 되기 시작한 날을 기록하여 하기 표 6에 나타내었다. 측정은 최대 28일까지 이루어졌으며, 시험과정을 구체적으로 나타내면 다음과 같다.To test the antimicrobial and antiseptic effect of the compositions of Examples 1 to 4 prepared above, bacteria or fungi were added to the sample and the change in the number of inoculum bacteria was checked, and the number of fungi or bacteria started to be 20 CFU/g or less. Recorded and shown in Table 6 below. Measurements were made up to 28 days, and the test procedure is as follows.
먼저, 화장료 조성물을 40 g씩 담은 후, 세균, 즉, 스타필로코커스 아우레우스(Staphylococcus aureus ATCC 6538), 세도모나스 애루지노사(Pseudomonas aeruginosa ATCC 15522) 및 에스케리치아 콜라이(Escherichia coli ATCC10536) 등의 혼합균액을 시료 1 g당 106 마리 수가 되도록 시료에 첨가, 혼합한 후 4 주간 보관하였다. 그 다음, 접종한 날로부터 1일, 7일 14일, 21일, 28일이 경과할 때마다 접종균 수의 변화를 체크하였다.First, after containing the cosmetic composition 40 g each, bacteria, that is, Staphylococcus aureus (Staphylococcus aureus ATCC 6538), Sedmonas aeruginosa (Pseudomonas aeruginosa ATCC 15522) and Escherichia coli (Escherichia coli ATCC10536) The mixture was added to the sample so that the number of 106 animals per 1 g of the sample was mixed and stored for 4 weeks. Then, the change in the number of inoculum bacteria was checked every time 1 day, 7 days 14 days, 21 days, and 28 days elapsed from the day of inoculation.
진균을 이용한 시험 과정은 세균을 이용한 시험과정과 종일하며, 진균으로 아스퍼질러스 나이거(Aspergillus niger ATCC 9642) 및 칸디다 알비칸스(Candida albicans ATCC 10231)를 사용하였다.The test procedure using fungi is the same as the test procedure using bacteria, and Aspergillus niger ATCC 9642 and Candida albicans ATCC 10231 were used as fungi.
평가항목Evaluation items | 접종균 수가 20 CFU/g 이하가 되기 시작한 날The day the number of inoculum bacteria started to reach 20 CFU/g or less | |||
실시예 1Example 1 | 실시예 2Example 2 | 실시예 3Example 3 | 실시예 4Example 4 | |
세균Germ | 14일14 days | 7일7 days | 7일7 days | 7일7 days |
진균Fungi | 14일14 days | 14일14 days | 7일7 days | 14일14 days |
실험결과, 본 발명의 실시예 1은 화학적 방부제를 사용하지 않았음에도 불구하고 14일 차부터 20 CFU/g 이하의 진균 또는 세균의 수를 나타내어 우수한 항균 및 방부 효과가 있음을 알 수 있었다. 특히 계피산 유도체를 2 중량% 이상 함유한 실시예 3의 경우 진균과 세균의 수가 급격하게 줄어들어 7일 차부터 20 CFU/g 이하의 진균 또는 세균의 수를 나타내어 훨씬 우수한 항균 및 방부 효과를 나타냈음을 확인할 수 있다.As a result of the experiment, Example 1 of the present invention was found to have excellent antibacterial and antiseptic effect by showing the number of fungi or bacteria below 20 CFU/g from the 14th day even though no chemical preservative was used. In particular, in the case of Example 3 containing more than 2% by weight of cinnamic acid derivatives, the number of fungi and bacteria rapidly decreased, indicating the number of fungi or bacteria of 20 CFU/g or less from the 7th day, and it was confirmed that the antibacterial and antiseptic effect was much better. Can be.
Claims (11)
- 하기 화학식 1로 표시되는 계피산 유도체 화합물:Cinnamic acid derivative compound represented by the following formula (1):<화학식 1><Formula 1>상기 식에서,In the above formula,R 1은 수소, C 1-C 2 알킬, OH, OCH 3, Cl 또는 Br이고,R 1 is hydrogen, C 1 -C 2 alkyl, OH, OCH 3 , Cl or Br,R 2는 수소, C 1-C 2 알킬, OH, OCH 3, Cl 또는 Br이고, R 3는 수소, C 1-C 2 알킬, OH, OCH 3, Cl 또는 Br이거나; 또는 R 2 및 R 3은 서로 연결되어 산소원자를 포함하는 헤테로고리를 형성하고,R 2 is hydrogen, C 1 -C 2 alkyl, OH, OCH 3 , Cl or Br, R 3 is hydrogen, C 1 -C 2 alkyl, OH, OCH 3 , Cl or Br; Or R 2 and R 3 are connected to each other to form a heterocycle containing an oxygen atom,여기서 R 21은 (CH 2) mR 211이며, m은 1 내지 2의 정수이며, R 211은 이고;Where R 21 is (CH 2 ) m R 211 , m is an integer from 1 to 2, and R 211 is ego;
- 제1항 내지 제3항 중 어느 하나의 항에 있어서, 상기 화합물은 항균 활성을 갖는 것을 특징으로 하는 화합물.The compound according to any one of claims 1 to 3, wherein the compound has antibacterial activity.
- 제1항 내지 제4항 중 어느 하나의 항에 있어서, 상기 화합물은 항균 활성 및 수용해성을 동시에 가지며, 상기 화합물의 상온에서의 수용해도는 1 내지 10%인 것을 특징으로 하는 화합물. The compound according to any one of claims 1 to 4, wherein the compound has antibacterial activity and water solubility at the same time, and the water solubility of the compound at room temperature is 1 to 10%.
- 제1항 내지 제5항 중 어느 하나의 항의 화합물, 또는 그의 염, 수화물 또는 용매화물을 포함하는 것을 특징으로 하는 항균용 조성물, 또는 이의 항균 용도.An antibacterial composition comprising the compound of any one of claims 1 to 5, or a salt, hydrate or solvate thereof, or an antibacterial use thereof.
- 제6항에 있어서, 상기 조성물은 상기 화합물, 또는 그의 염, 수화물 또는 용매화물을 0.1 내지 10 중량%의 함량으로 포함하는 것인 조성물 또는 이의 용도.The composition of claim 6, wherein the composition comprises the compound, or a salt, hydrate or solvate thereof, in an amount of 0.1 to 10% by weight.
- 제6항 또는 제7항에 있어서, 상기 조성물은 항균용 의약 조성물인 것인 조성물 또는 이의 용도.The composition or use thereof according to claim 6 or 7, wherein the composition is a pharmaceutical composition for antibacterial use.
- 제6항 내지 제8항 중 어느 하나의 항에 있어서, 상기 조성물은 항균용 화장료 조성물인 것인 조성물 또는 이의 용도.The composition or use thereof according to any one of claims 6 to 8, wherein the composition is an antibacterial cosmetic composition.
- 제6항 내지 제9항 중 어느 하나의 항의 조성물을 포함하는 제품으로서, 식품, 의약품, 의약외품, 생활용품 및 화장품으로 이루어진 군으로부터 선택되는 것을 특징으로 하는 제품.A product comprising the composition of any one of claims 6 to 9, characterized in that it is selected from the group consisting of food, pharmaceuticals, quasi-drugs, household goods and cosmetics.
- 제6항 내지 제9항 중 어느 하나의 항의 조성물을 사용하여, 미생물 성장을 억제하는 방법.A method for inhibiting microbial growth by using the composition of any one of claims 6 to 9.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180162125A KR102274599B1 (en) | 2018-12-14 | 2018-12-14 | Novel Cinnamic Acid Derivatives and Antimicrobial Compositions Comprising the Same |
KR10-2018-0162125 | 2018-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020122341A1 true WO2020122341A1 (en) | 2020-06-18 |
Family
ID=71075377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/008592 WO2020122341A1 (en) | 2018-12-14 | 2019-07-11 | Novel cinnamic acid derivative and antibacterial composition comprising same |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102274599B1 (en) |
WO (1) | WO2020122341A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060094874A1 (en) * | 2002-02-07 | 2006-05-04 | Council Of Scientific And Industrial Research | Novel substituted aryl alkenoic acid heterocyclic amides |
WO2009031202A1 (en) * | 2007-09-04 | 2009-03-12 | Shiseido Company Ltd. | Cinnamic acid derivatives and use thereof as ultraviolet absorber |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101534381B1 (en) | 2002-08-12 | 2015-07-09 | 론자 인코포레이티드 | Antimicrobial compositions |
-
2018
- 2018-12-14 KR KR1020180162125A patent/KR102274599B1/en active IP Right Grant
-
2019
- 2019-07-11 WO PCT/KR2019/008592 patent/WO2020122341A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060094874A1 (en) * | 2002-02-07 | 2006-05-04 | Council Of Scientific And Industrial Research | Novel substituted aryl alkenoic acid heterocyclic amides |
WO2009031202A1 (en) * | 2007-09-04 | 2009-03-12 | Shiseido Company Ltd. | Cinnamic acid derivatives and use thereof as ultraviolet absorber |
Non-Patent Citations (5)
Also Published As
Publication number | Publication date |
---|---|
KR20200073682A (en) | 2020-06-24 |
KR102274599B1 (en) | 2021-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10654799B2 (en) | Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms | |
DE68906231T2 (en) | Biocidal compounds. | |
DE69006398T2 (en) | N-substituted lauramides, their preparation and compositions containing them. | |
CN111031794B (en) | Antimicrobial mixture containing 4- (3-ethoxy-4-hydroxyphenyl) butan-2-one and organic acid compound, and cosmetic composition containing the same | |
JP2011074082A (en) | Antiseptic sterilizer and composition for application to human body | |
KR20160044071A (en) | Preservative composition containing methyl 3-acetyl-4-hydroxybenzoate as an active ingredient | |
KR20210111230A (en) | Antibacterial or conservative composition containing polyglycerine-3 | |
WO2020122341A1 (en) | Novel cinnamic acid derivative and antibacterial composition comprising same | |
CN105770999B (en) | A kind of composite biological material for eliminating bacterial biofilm | |
KR101585795B1 (en) | Preservative composition containing diethylene glycol monobenzyl ether as an active ingredient | |
JP4734293B2 (en) | Antiseptic disinfectant and human body composition | |
CN109730067A (en) | A kind of gemini quaternary ammonium salt fungicide and its preparation method and application of the rigid connection base containing naphthalene nucleus | |
JP2000159608A (en) | Antimicrobial composition | |
AU2003254560B2 (en) | Pyridyl-triazine derivatives as microbicidal active substances | |
WO2019115503A1 (en) | Propanediol monoacetate mononitrate | |
CN115607555B (en) | Use of compounds for inhibiting or killing mites | |
WO2015012652A1 (en) | Cosmetic composition for reducing skin wrinkles, containing atractylenolide iii as active ingredient | |
KR20120124084A (en) | Eugenol derivatives and its use | |
JP5289838B2 (en) | Antiseptic disinfectant and cosmetics, pharmaceuticals and foods containing the antiseptic disinfectant | |
EP1102536A1 (en) | Microbicidal active substances | |
KR102630903B1 (en) | New uses | |
EP3413716A1 (en) | Synthesis and application of an antimicrobial active | |
KR101957848B1 (en) | Composition for selective anti-bacterial comprising onion extract | |
CN115768517B (en) | Antimicrobial agent for non-human animals | |
KR102701405B1 (en) | Antimicrobial composition comprising polyamidoamine dendrimer derivatives as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19896944 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 01/10/2021) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19896944 Country of ref document: EP Kind code of ref document: A1 |